

# TechKnow

## INVEST ROADSHOW

MELBOURNE

GRAND HYATT HOTEL  
MELBOURNE, VIC



Maddocks

MYFIZIQ



InvestHK

EquitiesTracker



### THURSDAY 24 OCTOBER 2019

8.15am	Arrival Tea and Coffee		12.15pm	<b>Retech Technology Co Ltd</b> Edward Slade - Consultant	RTE
8.40am	<b>Official Conference Opening</b> Jaxon Crabb - Business Development Manager		12.30pm	<b>NeuroScientific Biopharmaceuticals Ltd</b> Brian Leedman - Chairman	NSB
8.45am	<b>Volpara Health Technologies Ltd</b> Dr Ralph Highnam - Chief Executive Officer	VHT	12.45pm	<b>OpenDNA Ltd</b> Bryan Carr - Managing Director & CEO	OPN
9.00am	<b>Novita Healthcare Ltd</b> Glenn Smith - Managing Director	NHL	1.00pm	<b>Innovyz Capital</b> Brett Jackson - Co-Founder & Executive Director	
9.15am	<b>Osteopore Ltd</b> Geoff Pocock - Director	OSX	1.15pm	LUNCH	
9.30am	<b>Cyclopharm Ltd</b> James McBrayer - Chief Executive Officer	CYC	2.00pm	<b>1st Group Ltd</b> Klaus Bartosch - Managing Director & Co-Founder	1ST
9.45am	<b>ResApp Health Ltd</b> Brian Leedman - Vice President, Corporate Affairs	RAP	2.15pm	<b>Mobilicom Ltd</b> Oren Elkayam - Chief Executive Officer	MOB
10.00am	<b>Dragontail Systems Ltd</b> Ido Lavanon - Chief Executive Officer	DTS	2.30pm	<b>PainChek Ltd</b> David Allsopp - Head of Business Development	PCK
10.15am	<b>OpenLearning</b> Adam Brimo - Chief Executive Officer		2.45pm	<b>Antisense Therapeutics Ltd</b> Mark Diamond - Managing Director / CEO	ANP
10.30am	<b>Noxopharm Ltd</b> Dr Graham Kelly - Executive Chairman	NOX	3.00pm	<b>Amaero International Ltd</b> Stuart Douglas - Executive Director Business Strategy & Development	
10.45am	MORNING TEA		3.15pm	<b>K-TIG Ltd</b> David Williams - Chief Executive Officer	KTG
11.15am	<b>iCetana</b> Matthew Macfarlane - Chief Executive Officer		3.30pm	<b>Pointerra Ltd</b> Ian Olson - Managing Director	3DP
11.30am	<b>MyFiziq Ltd</b> Vlado Bosanac - Chief Executive Officer	MYQ	3.45pm	<b>First Graphene Ltd</b> Warwick Grigor - Chairman	FGR
11.45am	<b>InteliCare</b> Jason Waller - CEO & Managing Director		4.00pm	<b>Maddocks Investment Panel Discussion</b>	
12.00pm	<b>Nyrada</b> James Bonnar - Chief Executive Officer		4.30pm	CLOSING DRINKS SPONSORED BY <b>MADDOCKS</b>	
			5.00pm	CONFERENCE CLOSE	

#Techknow19



Follow us on Twitter  
@VEvents\_RIU



Follow us on Instagram  
@instagram.com/verticalevents



# Techknow

## INVEST ROADSHOW

Sydney, NSW Tuesday 22 October 2019 The Westin Hotel  
Melbourne, VIC Thursday 24 October 2019 Grand Hyatt Hotel

SHOWCASING COMPANIES: CLICK ON THE COMPANY'S LOGO TO BE DIRECTED TO THEIR WEBSITE

Thanks to our Sponsors:

**MYFIZIQ**

Maddocks



Invest**HK**



**EquitiesTracker**



**1st Group Ltd (ASX:1ST)**

1st Group is an ASX listed digital health group building Australia's leading health services portal, MyHealth1st.com.au, Australia's online pet service portal PetYeti.com.au and corporate and government solutions platform GoBookings.com. These integrated platforms provide an easy to use online search and appointment booking service and offer a range of value-added apps and services that facilitate digital patient and customer engagement. We improve lives by connecting consumers to a variety of healthcare services and information anytime, anywhere, so they can get well sooner and stay well longer.

1st Group launched its first platform, MyHealth1st.com.au in 2012, and PetYeti.com.au around 2 years ago. Both platforms are supported by the GoBookings system, and these platforms now integrate with over 45 practice management software systems. Today the company supports over 10,000 sites/practices across Australia and New Zealand with an addressable market in excess of 150,000 sites/practices and total potential market size of \$1.9Bn per annum based on today's fees and known product/service range.

For more information visit: [1stGrp.com](http://1stGrp.com), [MyHealth1st.com.au](http://MyHealth1st.com.au), [PetYeti.com.au](http://PetYeti.com.au) and [GoBookings.com](http://GoBookings.com)

**AMAERO**  
ADDITIVE MANUFACTURING

**Amaero International Ltd**

Amaero International is recognised as world leaders in 3D printing of precision metal components for Aerospace and Defence purposes. Their proprietary processes and knowhow has led them to an enviable position of being accredited suppliers to such companies as Boeing, Raytheon, Northrop Grumman, Thales & Virgin Australia. Amaero's heritage in this rapidly growing sector is impressive, being the first company in the world to 3D manufacture high temperature critical parts for jet engines and the first company to 3D print an aerospace rocket engine. Today Amaero leads the industry in the range of 3D printed alloys that meet aerospace standards and is developing new IP in precision 3D printing machines and proprietary super alloys used in 3D printing for precision components. Due to the demand from their Defence and Aerospace clients, Amaero must now scale their operations to include multiple international footprints. Backed by 40+ research scientist from Monash University Centre for Additive Manufacturing, Amaero is positioned globally as the go to company for complex certified aviation and defence components. Amaero welcomes the opportunity to present their Pre-IPO and IPO investment strategy to the Techknow Invest Roadshow attendees.

For more information visit: [www.amaero.com.au](http://www.amaero.com.au)

**Antisense Therapeutics Ltd (ASX:ANP)**



Antisense Therapeutics Ltd (ASX:ANP) is an Australian publicly listed biopharmaceutical company, developing and commercialising antisense pharmaceuticals for large unmet markets. The products are in-licensed from Ionis

Pharmaceuticals Inc. (NASDAQ:IONS), world leaders in antisense drug development and commercialisation. ANP's pipeline consists of ATL1102, an antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4) that has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis and ATL1103 designed to block GHR production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly. The Company is currently conducting a Phase II clinical trial of ATL1102 in Duchenne Muscular Dystrophy patients at the Royal Children's Hospital, Melbourne.

For more information visit: [www.antisense.com.au](http://www.antisense.com.au)

**cyclopharm** **Cyclopharm Ltd (ASX:CYC)**



Cyclopharm is a company in the diagnostic imaging field specialising in lung health. We achieve this positioning through our proprietary medical device and pharmaceutical products under the name TECHNEGAS. TECHNEGAS has become the industry gold-standard in diagnostic functional lung imaging technology. We distribute our products in 57 countries throughout the world with over 1500 nuclear medicine departments utilizing TECHNEGAS. To date, over 4.2 million patient procedures are recorded.

TECHNIGAS is a structured ultra-fine dispersion of radio-labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaceed for a few seconds at around 2,750C. The resultant gaseous substance is inhaled by the patient via a breathing apparatus, which then allows multiple views and tomographic imaging with a nuclear medicine camera for a superior functional imaging of the alveolar spaces of the lungs.

For more information visit: [www.cyclopharm.com](http://www.cyclopharm.com)

**Dragontail** **Dragontail Systems Ltd (ASX:DTS)**

systems

Dragontail Systems Ltd is the leading B2B end-to-end provider of revolutionary software and analytical solutions, using artificial intelligence (AI), for the optimisation of the food preparation and delivery industry. The Company's revolutionary 'Algo' kitchen optimisation and delivery platform and the AI QT - quality control camera have been implemented and appreciated by the Worlds largest QSR brands, achieving over 400% 12 months installations growth in over 1,500 store globally and rapidly increasing. Dragontail now has a global team of over 50 staff working in 7 countries and is poised to meet future pipeline opportunities. This has included investing deeply in the human resources needed to advance our cutting edge AI. For more information visit: [www.dragontail.com](http://www.dragontail.com)



first graphene

The world's leading graphene company

**First Graphene Ltd (ASX:FGR)**

Investment Highlights:

- Global leader in the commercialisation of Graphene into industry: FGR has a robust manufacturing and delivery platform which produces a high quality graphene material. This advanced material is being commercialised out of its WA facility for use in end-user market verticals. These include: Polymer liners for mining equipment and other wear liner applications; composites for leisure and recreational products, such as boats, and also for footwear. Future applications may include automotive coolants; fire retardants; and cement products. The number of applications is diverse and FGR is the only company able to provide the polymer and composites markets with bulk quantities of graphene material.

- Graphene is forecast to create a +\$300M materials market by 2022 that supports the downstream multi-billion dollar industries across transportation, construction, industrial products, energy storage and electronics. Addition of <1% PureGRAPH™ by weight typically gives >40% improvement in performance of key parameters e.g. tensile strength, abrasion resistance, thermal conductivity.

- Operating Graphene production facility in WA: Low capital cost and short timeline to construct a fully operational 100 tpa facility that has the potential to deliver \$10M in operating cash flow. Expansion capacity available to support global market opportunities as they move through the sales cycle. Sub \$2m to scale up and double capacity.

- Low manufacturing costs, secured greenfeed supply delivers high margin product: target economics are to secure margins of ~\$100/kg to convert the company to a cash breakeven operation in 2020.

- Sales traction now coming through: commercial progress has been made with multiple market segments with high volume applications. Sales contracting in progress with multiple buyers to provide a steady stream of news flow.

For more information visit: [www.firstgraphene.net](http://www.firstgraphene.net)

**iCetana** iCetana

SEE THINGS DIFFERENTLY

iCetana is a world leader in real-time AI-assisted video monitoring software with customers on four continents. The patented video motion anomaly detection algorithms developed by iCetana transform

security operations centres and identify risk events over a wide range of industries. iCetana is pursuing a listing on the ASX in the coming months on the back of substantial pipeline growth particularly in the software-as-a-service part of the business. iCetana has secured strategic value added reseller relationships with key security system integrators such as Chubb (AU), Delco Security (Canada) and Convergent Technologies (US) which is driving new revenue growth. Customers include Crown Casino, Woodside Petroleum, Swinburne University, CapitalOne bank in the US, Mount Royal University in Calgary and Majid Al Futtaim shopping malls across the Middle-East. For more information visit: [www.icetana.com](http://www.icetana.com)

**INNOVYZ** Innovyz Capital

At Innovyz we turn great ideas into great companies. We specialise in working with universities, research institutions and inventors to bring research and invention to market. With successes like K-Tig, Titomic and soon, Amaero, Innovyz is the leading hardware and manufacturing commercialisation organisation in Australia.

For more information visit: [www.innovyz.com](http://www.innovyz.com)



**InteliCare**

InteliCare provides family and care givers a real-time view of the well-being of people in an independent living environment. This real-time view and the ability for family to be informed and act when something may be wrong reduces potential risks for seniors or people with disability living at home alone. InteliCare uses data from in "smart" sensors to build a model of normal domestic routine within a home. An early view of deviations from routine may indicate a health or wellbeing issue, that when addressed will avoid complications leading to potential future higher levels of care. A range of sensors and "insights" can be activated to address the risks associated with ageing or other situations and provide family and carers with information to guide conversations that may address issues before they escalate into health or safety problems. For more information visit: [www.intelicare.com.au](http://www.intelicare.com.au)

**K-TIG** K-TIG Ltd (ASX:KTG)

K-TIG is commercialising a high-speed, high-productivity welding technology that was originally developed by the CSIRO. The K-TIG System has a unique competitive advantage as it is able to perform a conventional 6-hour weld in less than 3 minutes producing overall cost savings of 80-95% and reductions in welding time in excess of 90%. K-TIG boasts a strong customer base with its customers spanning 20 countries and including the likes of GE, Siemens, Bilfinger, Doncasters, Defence Materials Technology Centre and the UK Nuclear Advanced Manufacturing Research Centre. K-TIG continues to change the economics of fabrication for its customers through the introduction of its Welding-as-a-Service (WaaS) business model, service delivery via its cloud-linked controller and in turn generating long-term recurring revenue streams for the company from a broad global customer base. For more information visit: [www.k-tig.com](http://www.k-tig.com)

**Maddocks**

Maddocks

Maddocks is an independent Australian law firm that provides a full range of premium legal services to corporations, businesses and governments throughout Australia and internationally. We advise clients across a range of sectors including technology, education, government, healthcare and infrastructure, from our Canberra, Melbourne and Sydney offices. We have a team of experienced Corporate and capital markets lawyers who have a proven track record assisting companies throughout their lifecycle: from their early stages establishing and developing their businesses, through growth financing to advising issuers and lead managers / underwriters in their capital markets transactions. Our team assists both Australian and foreign companies with their IPOs and listing on the ASX Our partners are recognised for their hands-on and commercial approach to the myriad of legal issues involved in an IPO. We aim to build long-term relationships with our clients through their IPO and into their listed life, supporting companies in their future transactions, compliance and capital raisings as they continue to grow and develop.

For more information visit: [www.maddocks.com.au/services/equity-capital-markets/](http://www.maddocks.com.au/services/equity-capital-markets/)

Follow us on Twitter: @VEEvents\_RIU

Follow us on Instagram: [instagram.com/verticalevents](https://www.instagram.com/verticalevents)

Vertical Events Pty Ltd

Suite 13-14, 186 Hay Street Subiaco WA 6008 | PO Box 1153 Subiaco WA 6904

T: (61 8) 9388 2222 | E: [info@verticalevents.com.au](mailto:info@verticalevents.com.au) | W: [www.verticalevents.com.au](http://www.verticalevents.com.au)



Investment Conference Specialists

# Techknow

## INVEST ROADSHOW

Sydney, NSW Tuesday 22 October 2019 The Westin Hotel  
Melbourne, VIC Thursday 24 October 2019 Grand Hyatt Hotel

SHOWCASING COMPANIES: CLICK ON THE COMPANY'S LOGO TO BE DIRECTED TO THEIR WEBSITE

### **MOBILICOM** Mobilicom Ltd (ASX:MOB)

Mobilicom Limited is a high-tech company that designs, develops and delivers communication solutions for mission-critical and remote mobile private networks that can operate without the need for existing infrastructure. Mobilicom products and technologies are based on an innovative approach that merges 4G and Mobile MESH technologies. Mobilicom offers a large solution portfolio that has been deployed worldwide. Mobilicom has two business entities. The first is Mobilicom's core business entity, with solutions that cater to mission-critical communication in the Government and Enterprise sector with applications in unmanned platforms, disaster relief and public safety, and offshore and remote areas. The second is its SkyHopper business entity, an end-to-end equipment and solution provider, which targets the Commercial Drone & Robotics sector. SkyHopper's holistic approach enables commercial drone and robotics manufacturers to focus on their own business objectives by reducing time-to-market, minimizing resource expenditures and increasing their chances for success.  
**For more information visit: [www.mobilicom.com](http://www.mobilicom.com)**

### **MYFIZIQ** MyFiziq Ltd (ASX:MYQ)

MyFiziq is a revolutionary mobile application developed and patented to measure and track the human form via a smart phone. We embed our technology in a partner's application, using images captured from your smartphone to create a representation of an individual in the form of a 3D avatar with accurate circumference measurements and body composition. Partners embed our SDKs (Software Development Kits) into their new or existing apps, and then customize the experience to satisfy their branding requirements. MyFiziq is an augmentor of current technologies, rather than a disruptor. We partner with highly scalable existing applications and provide our partners with a deeper insight into the data they currently retrieve from their users. When consumers want to track their changes from diet or training or simply buy insurance or clothing online, the end result is a drive toward understanding an individual's dimensions or the changes they are undergoing. MyFiziq provides that missing link in other ecosystems. **For more information visit: [www.myfiziq.com](http://www.myfiziq.com)**

### **NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)**

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) is a biotech company focused on developing novel peptide-based drugs, called Emtins, which have the potential to treat neurodegenerative conditions. Emtin peptides are modelled on the active sites of a protein expressed in the brain following brain injury. NSB's lead peptide candidate, EmtinB, is most advanced as a treatment for Alzheimer's disease. EmtinB has been shown to induce the survival and regrowth of neurons through binding to specific receptors expressed by neuronal cells. The peptide offers a novel therapeutic treatment pathway for neurodegenerative diseases that are currently without effective treatment options, such as Alzheimer's disease.  
**For more information visit: [www.neuroscientific.com](http://www.neuroscientific.com)**

### **NOVITA HEALTHCARE** Novita Healthcare Ltd (ASX:NHL)

Novita Healthcare is based in Melbourne, Australia, and positions itself at the forefront of innovative medical technologies with Tali Health as the foundation product for the future. As a team of neuroscientists, software engineers, game developers and all-round talented individuals, our vision is to be a leader in the assessment and treatment of childhood attention difficulties. With the aim to assist children in reaching their full potential by providing engaging training software clinically proven to improve core cognitive performance. Under the leadership of the TALI Health board of directors, our team of experts' design, develop, and evaluate training exercises that target core issues in early childhood and academic skills.  
**For more information visit: [www.novitahealthcare.com.au](http://www.novitahealthcare.com.au)**

### **NOXOPHARM** Noxopharm Ltd (ASX:NOX)

Noxopharm Ltd (ASX:NOX) is an Australian-based drug development company, with offices in Sydney and New York. It focuses on cancer drug technology and in particular, the potential benefits to cancer patients in being able to increase their responsiveness to radiotherapies and standard of care chemotherapies but with lowered side-effects. Veyonda® (formerly known as NOX66) is the first pipeline drug candidate, with later generation drug candidates under investigation in an active R&D program. Veyonda® is currently being trialled in two prostate cancer studies, with other patient trials in planning. Research is underway exploring Veyonda's active ingredient idronoxil's (IDX) potential to act as a well-tolerated STING agonist.  
**For more information visit: [www.noxopharm.com](http://www.noxopharm.com)**

### **Nyrada Inc.**

Nyrada is a pre-clinical stage, drug development company specialising in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. The Company's vision is to become a high growth bio-pharmaceutical company specialising in drug discovery and early stage drug development, based mainly around the benzopyran molecular scaffold and focusing on areas of substantial unmet clinical need, where few if any, effective or well-tolerated therapies exist. The Company has four current drug development programs:  
**Cardiovascular: Neuroprotection: Inflammation/pain: Inflammation/autoimmunity**  
**For more information visit: [www.nyrada.com](http://www.nyrada.com)**

### **OPENDNA** OpenDNA Ltd (ASX:OPN)

The OpenDNA Group of companies provides fully integrated digital marketing and customer acquisition services focusing on driving online sales of products and services for its clients. Powered by the OpenDNA hyper personalisation and profiling Artificial Intelligence System, OpenDNA provides personalised real-time, targeted marketing. With a key focus on driving sales in Australia and China the Company's Roolife online e-Commerce marketplace assists businesses to sell directly to Chinese consumers and accept payment via the WeChat and Alipay mobile payments platforms. Roolife's key positioning is about knowing and remaining connected with Chinese consumers, allowing brands to continually sell products to Chinese Consumers based on their profiles and purchasing behaviours.  
**For more information visit: [www.opendna.ai](http://www.opendna.ai)**

### **openlearning** OpenLearning

OpenLearning is a complete SaaS solution for education providers and corporations to deliver both formal and non-formal online education and training, including micro-credentials, online degrees and continuing professional development. We provide a next-generation lifelong learning platform, learning design expertise, and a global marketplace of world-class courses. With over 2.4 million enrolments across 180 countries and partnerships with Australia's top universities, OpenLearning is at the forefront of a new wave of education delivery. We believe that meaningful, transformative learning happens when learners are inspired, challenged and motivated by more than grades. By leveraging technology and educational expertise, our goal is to enable education providers worldwide to prepare their learners for the future of work.  
**For more information visit: [www.openlearning.com](http://www.openlearning.com)**

### **Osteopore Ltd (ASX:OSX)**

Osteopore specialises in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone healing. Osteopore's products are manufactured in-house using 3D printing technology that is precise and allows for customisation of shape and geometry. The unique 3D printed biomimetic micro architecture of the 3D scaffolding which is contained within the Osteopore products provides for infiltration of cells and blood vessels, both of which play key roles in wound healing and tissue repair. Osteopore products are made of a US FDA approved polymer called polycaprolactone (PCL). PCL is bioresorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone.  
**For more information visit: [www.osteopore.com](http://www.osteopore.com)**

### **PainChek Ltd (ASX:PCK)**

PainChek Ltd (ASX:PCK) PainChek's vision is to be first to market with innovative pain assessment products and services that improve quality of life for people in pain. PainChek® is the world's first pain assessment tool that has regulatory clearance in Australia and Europe. Using AI and facial recognition technology, PainChek® provides carers across multiple clinical areas with three important new clinical benefits: The ability to identify the presence of pain, when pain isn't obvious, to quantify the severity level of pain, when pain is obvious, and to monitor the impact of treatment to optimise overall care.  
**For more information visit: [www.painchek.com](http://www.painchek.com)**

### **Pointerra Ltd (ASX:3DP)**

Pointerra provides an end-to-end Data as a Service (DaaS) solution for managing, visualising, working in, analysing and sharing massive 3D datasets.  
**For more information visit: <http://www.pointerra.com/>**

### **ResApp Health Ltd (ASX:RAP)**

ResApp Health Ltd (ASX:RAP) is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease. We are creating easy to use, affordable, clinically validated and regulatory approved diagnostic tools that only require a smartphone. Our solutions are designed to be easily integrated into existing telehealth solutions and we are also working on apps to provide respiratory disease diagnosis and management directly to consumers and healthcare providers. ResApp is similarly developing an app for the diagnosis of sleep apnea. ResApp was founded in September 2014 to commercialise technology developed by Associate Professor Udantha Abeyratne at The University of Queensland who has received funding by the Bill and Melinda Gates Foundation.  
**For more information visit: [www.resapphealth.com.au](http://www.resapphealth.com.au)**

### **RETECH** Retech Technology Co. Ltd (ASX:RTE)

Retech Technology Co., Limited is China's leading e-learning services and technology provider. The market for corporate e-learning in China is in an early, growth stage, and is estimated at approximately US\$1.5bn in size, compared to a US\$100bn global corporate e-learning market. Retech provides its clients with high quality, customized online training solutions and training management solutions. Retech's products include e-learning solutions, learning analytics, customized and pre-prepared courses from our library of high quality training courses, ESG reporting and training for our clients, and online language training programs. Customers include Bank of China, Ping An Insurance and Mercedes Benz. Based in Shanghai, Retech has over 260 staff, 80% of which are involved in courseware development and R&D. In the year to December 2018, our net profit was A\$10 million equivalent, growing 30% over 2017. As at end September 2019, our market capitalisation was A\$93 million.  
**For more information visit: [www.retech-rte.com](http://www.retech-rte.com) or contact [investors@rettech-rte.com](mailto:investors@rettech-rte.com)**

### **volpara** Volpara Health Technologies Ltd (ASX:VHT)

Volpara Health Technologies Ltd (ASX: VHT) is a leading medical technology company dedicated to the early detection of breast cancer by improving the quality of mammographic screening. Volpara's artificial intelligence imaging algorithms enable breast imaging centres around the world to provide personalised, high-quality breast cancer screening based on automated, objective measurements of breast density, positioning, radiation dose, and compression. This work is supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking, and a volume of peer-reviewed publications unrivalled in the breast density industry. In 2019 Volpara acquired Seattle-based MRS Systems, Inc. (MRS), giving the company a stronger US presence and an integrated product suite which will help detect breast cancer earlier. MRS is a medical software company that provides comprehensive patient tracking and communication, and a radiology reporting platform for subspecialty radiology applications including breast and lung imaging. **For more information visit: [www.volparasolutions.com](http://www.volparasolutions.com)**

Follow us on Twitter: @VEEvents\_RIU

Follow us on Instagram: [instagram.com/verticalevents](https://www.instagram.com/verticalevents)

Vertical Events Pty Ltd

Suite 13-14, 186 Hay Street Subiaco WA 6008 | PO Box 1153 Subiaco WA 6904

T: (61 8) 9388 2222 | E: [info@verticalevents.com.au](mailto:info@verticalevents.com.au) | W: [www.verticalevents.com.au](http://www.verticalevents.com.au)

 **events**  
Investment Conference Specialists